Tempus AI launches angiosarcoma research collaboration with Angiosarcoma Awareness

Tempus Al

Tempus Al

TEM

0.00
  • Tempus AI launched a research collaboration with Angiosarcoma Awareness to speed data-driven research in angiosarcoma, a rare aggressive cancer.
  • No study results were presented; the work will generate future findings from Tempus’ dataset of about 600 de-identified cases with paired DNA and RNA data.
  • The effort aims to sharpen understanding of disease biology, surface potential treatment opportunities, and reduce the data constraints that have limited rare-cancer research.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260625255804) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.